A. Luber

发表

Antiretroviral therapy for pregnant HIV-infected women.

B. Dong, A. Luber, 2000, Annals of internal medicine.

Prevention of adverse events in hospitalized patients using an antimicrobial review program.

B. Guglielmo, J. Flaherty, R. Corelli, 1999, Western Journal of Medicine.

Famciclovir for Treatment of Herpesvirus Infections

J. Flaherty, A. Luber, 1996, The Annals of pharmacotherapy.

Steady‐state pharmacokinetics of once‐daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers *

I. Frank, C. Peloquin, A. Luber, 2007, HIV medicine.

Open Access Journal of the International Aids Society Genetic Barriers to Resistance and Impact on Clinical Response

A. Luber, Andrew D Luber, 2005 .

Hypothermia following the intravenous administration of amphotericin B.

B. Guglielmo, R. Jacobs, A. Luber, 1996, Clinical Infectious Diseases.

Risk factors for amphotericin B-induced nephrotoxicity.

B. Guglielmo, L. Maa, M. Lam, 1999, The Journal of antimicrobial chemotherapy.

Plasma Amprenavir Pharmacokinetics and Tolerability following Administration of 1,400 Milligrams of Fosamprenavir Once Daily in Combination with either 100 or 200 Milligrams of Ritonavir in Healthy Volunteers

P. Ruane, M. Shelton, Y. Lou, 2006, Antimicrobial Agents and Chemotherapy.

Therapeutic drug monitoring in HIV infection: current status and future directions

R. Haubrich, M. Kurowski, C. Fletcher, 2002, AIDS.

Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes.

A. Luber, 2005, The AIDS reader.

Ceftriaxone therapy for staphylococcal osteomyelitis: a review.

B. Guglielmo, R. Jacobs, A. Luber, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetic Considerations for Selection of HAART in Treatment-Naive HIV-Infected Individuals, 2008: More Than it Seems?

A. Luber, 2008 .

Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus.

R. Haubrich, C. Flexner, S. Piscitelli, 2001, Journal of acquired immune deficiency syndromes.

Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health

H. Ertl, S. Currie, A. Luber, 2022, Frontiers in Immunology.

Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci.

B. Guglielmo, R. Jacobs, A. Luber, 1996, The Journal of infectious diseases.

K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.

P. Ruane, A. Luber, 2004, MedGenMed : Medscape general medicine.

The Evolution of an Antimicrobial Review System at a University Hospital

A. Luber, 1997 .

Treatment strategies for highly treatment-experienced HIV-infected patients

A. Luber, 2005, Expert review of anti-infective therapy.